

## Scientific Poster Presentations, I

Monday, October 17

Convention Center: Exhibit Hall A

11:30 a.m.–1:15 p.m.

### ENCORE PRESENTATIONS

Abstracts marked with an “E” are Encore Presentations. Encore Presentations undergo the same peer-review process as all other presentations, but they may have been presented elsewhere or published in abstract form before the 2011 Annual Meeting. For presentations, the abstract title, authors, and original citation (if provided) are published.

### FINALISTS IN ABSTRACT AWARDS COMPETITION

Abstracts marked with an “F” are finalists for the Best Student Poster, Best Resident and Fellow Poster, and Best Paper Awards. These papers were selected by a special panel of reviewers. Award winners for the Best Student Poster will be announced at 1:00 p.m. on Monday, October 17, in Exhibit Hall A of the David L. Lawrence Convention Center. Award winners for the Best Resident and Fellow Poster and Best Paper will be announced at 9:45 a.m. Tuesday, October 18, in Exhibit Hall A of the David L. Lawrence Convention Center.

### ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoconomics, and pharmacoepidemiology.

#### ADR/Drug Interactions

##### 1. Comparison of Online Drug Interaction Databases to Evaluate Antiretroviral Medication Interactions.

*Tomasz Z. Jodlowski, Pharm.D., BCPS (AQ-ID),<sup>1</sup> Priti N. Patel, Pharm.D., BCPS,<sup>1</sup> Nicole M. Maisch, Pharm.D.,<sup>1</sup> Donna Mildvan, M.D.<sup>2</sup>; (1)St. John’s University College of Pharmacy and Allied Health Professions, Queens, NY; (2)Beth Israel Medical Center, New York, NY*

##### 2. Comparing the Type and Severity of Drug Interactions Among Different ICUs.

*Pamela L. Smithburger, Pharm.D., BCPS, Sandra L. Kane-Gill, Pharm.D., M.S., FCCM, FCCP, Amy L. Seybert, Pharm.D.; University of Pittsburgh School of Pharmacy, Pittsburgh, PA*

##### 4E. Evaluating the Occurrence of QT Prolongation Resulting from Drug-Drug Interactions.

*Michael J. Armahizer, Pharm.D.,<sup>1</sup> Sandra Kane-Gill, Pharm.D., M.S., FCCM,<sup>2</sup> Pamela L. Smithburger, Pharm.D., BCPS,<sup>2</sup> Amy L. Seybert, Pharm.D.<sup>2</sup>; (1)UPMC Presbyterian, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA*

##### 5E. Improving Adverse Drug Event Detection in Critically Ill Patients Through Intensive Care Unit Transfer Summary Screening.

*Ananth Anthes, Pharm.D.,<sup>1</sup> Lisa M. Harinstein, Pharm.D., BCPS,<sup>2</sup> Pamela L. Smithburger, Pharm.D., BCPS,<sup>3</sup> Amy L. Seybert, Pharm.D.,<sup>3</sup> Sandra L. Kane-Gill, Pharm.D., M.S.,*

FCCM, FCCP<sup>3</sup>; (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)Cleveland Clinic, Cleveland, OH; (3)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

## Adult Medicine

### **7. Evaluation of an iPad to Provide Warfarin Video Education in the Inpatient Setting.**

*Jenny J. Kim, Pharm.D.*,<sup>1</sup> Rima A. Mohammad, Pharm.D.,<sup>2</sup> Kim C. Coley, Pharm.D.,<sup>2</sup> Amy C. Donihi, Pharm.D.<sup>2</sup>; (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

### **8. Evaluation of a Pharmacy-Driven Renal Dosing Program.**

Katherine J. Rable, Pharm.D., *Andrew J. Crannage, Pharm.D., BCPS*; St. John's Mercy Medical Center and St. Louis College of Pharmacy, St. Louis, MO

### **9. Risk Factors for Venous Thromboembolism in Patients with Cirrhosis.**

*Kelly A. Walsh, Pharm.D.*; University of Kentucky HealthCare, Lexington, KY

### **10. As-Needed Intravenous Antihypertensive Therapy and Blood Pressure Control.**

*Melissa Lipari, Pharm.D.*,<sup>1</sup> Lynette R. Moser, Pharm.D.,<sup>2</sup> Elizabeth A. Petrovitch, Pharm.D., BCPS,<sup>1</sup> Margo Farber, Pharm.D.,<sup>3</sup> John Flack, M.D., MPH<sup>4</sup>; (1)Harper University Hospital, Detroit, MI; (2)Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI; (3)Detroit Medical Center, Detroit, MI; (4) Wayne State University School of Medicine, Detroit, MI

### **11. Pharmacy Department Commitment to a Multidisciplinary Stroke Response Team.**

Matthew J. Korobey, Pharm.D., BCPS,<sup>1</sup> *Andrew J. Crannage, Pharm.D.*,<sup>2</sup> Julie A. Murphy, Pharm.D., BCPS,<sup>2</sup> Judd Jensen, M.D.,<sup>1</sup> B.J. Hipsky, R.N., MSN<sup>1</sup>; (1)St. John's Mercy Medical Center, St. Louis, MO; (2)St. Louis College of Pharmacy and St. John's Mercy Medical Center, St. Louis, MO

## Ambulatory Care

### **12. Impact of Change in Duration of Therapy with Ursodiol After Gastric Bypass Surgery.**

*Margaret Malone, Ph.D., FCCP*,<sup>1</sup> Jennifer Lindstrom, M.D.,<sup>2</sup> Christine Gallati, B.S.<sup>2</sup>; (1)Albany College of Pharmacy and Health Sciences, Albany, NY; (2)Albany Medical College, Albany, NY

### **13. Effectiveness of Dietary Sodium Intervention Provided by a Clinical Pharmacist to Ambulatory Patients with Heart Failure.**

*Grace L. Earl, Pharm.D.*,<sup>1</sup> Annette Lista, Pharm.D. Candidate,<sup>1</sup> Susan Youssef, Pharm.D. Candidate,<sup>1</sup> Laura Pontiggia, Ph.D.,<sup>2</sup> Andrew Peterson, Ph.D.<sup>3</sup>; (1)University of the Sciences, Philadelphia College of Pharmacy, Philadelphia, PA; (2)University of the Sciences, Misher College of Arts and Sciences, Philadelphia, PA; (3)University of the Sciences, Mayes College of Health Care Business and Policy, Philadelphia, PA

### **14. Assessment of Insulin Pens in Urban Teaching Hospital Outpatient Clinics.**

*Andrea R. Gauld, Pharm.D.*,<sup>1</sup> Brigitte L. Sicat, Pharm.D.,<sup>2</sup> Brian Baird, Pharm.D.<sup>1</sup>; (1)Virginia Commonwealth University Health System, Richmond, VA; (2)Virginia Commonwealth University School of Pharmacy, Richmond, VA

**15. Homeless and Housed Patients' Access to Treatment at a Pharmacist-Led Smoking Cessation Clinic.**

*Sharon E. Connor, Pharm.D.,<sup>1</sup> Deborah M. Scharf, Ph.D.,<sup>2</sup> Lauren J. Jonkman, Pharm.D., BCPS,<sup>1</sup> Mary I. Herbert, M.S., MPH<sup>3</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)Department of Psychiatry, University of Pittsburgh and RAND Corporation, Pittsburgh, PA; (3)UPMC Department of General Internal Medicine, Pittsburgh, PA*

**16. Malignancy and Warfarin-Mediated Anticoagulation: Lower Initial Dose Requirements, but Greater Long-term Instability, Adverse Events, and Intensity of Management.**

*Holly H. Chiu, Pharm.D.,<sup>1</sup> Megan B. Bestul, Pharm.D.,<sup>1</sup> Peter Whittaker, Ph.D.<sup>2</sup>; (1) Beaumont Hospital, Royal Oak, MI; (2)Wayne State University School of Medicine, Cardiovascular Research Institute and Department of Emergency Medicine, Detroit, MI*

**17. Use of Low-Molecular-Weight Heparin (LMWH) in Pregnancy: A Pharmacodynamic Modeling Study.**

*Tara E. Gleason, Pharm.D.,<sup>1</sup> Nancy L. Shapiro, Pharm.D.,<sup>1</sup> Larisa H. Cavallari, Pharm.D.,<sup>1</sup> Edith A. Nutescu, Pharm.D.,<sup>1</sup> Michelle Kominiarek, M.D.,<sup>2</sup> Judith U. Hibbard, M.D.<sup>2</sup>; (1)University of Illinois at Chicago College of Pharmacy, Chicago, IL; (2)University of Illinois College of Medicine, Chicago, IL*

**18. Increased Goal Attainment After Conversion from Rosuvastatin to Simvastatin in a Community Health Clinic.**

*Joel C. Marrs, Pharm.D., BCPS,<sup>1</sup> Sarah L. Anderson, Pharm.D., BCPS,<sup>1</sup> Karen E. Snow, Pharm.D.,<sup>2</sup> Joseph J. Saseen, Pharm.D., FCCP, BCPS<sup>1</sup>; (1)University of Colorado School of Pharmacy, Aurora, CO; (2)Denver Health Medical Center, Denver, CO*

**19. Evaluation of Two Education Methods for Patient Knowledge in Patients Recently Started on Warfarin.**

*Lisa Potts, Pharm.D., BCPS, Cari Cristiani, Pharm.D., BCPS, Jun-Yen Yeh, Ph.D.; Cleveland Clinic, Cleveland, OH*

**Critical Care**

**45. Comparison of Short-term Pulmonary Improvement Associated with Inhaled Nitric Oxide and Inhaled Epoprostenol for Acute Respiratory Distress Syndrome.**

*Bridget A. Scoville, Pharm.D., Paul Tan, Pharm.D., Donald W. Johnson, Pharm.D., Patrick Aaronson, Pharm.D.; Shands Jacksonville Medical Center, Jacksonville, FL*

**46. Medication Errors and Associated Factors in the Intensive Care Unit of Jimma University Specialized Hospital in Ethiopia, April 2011.**

*Asrat Agalu, M.S., BSP Pharm; Wollo University, Dessie Ethiopia, Jimma, Ethiopia*

**48. Pharmacist Publications in Critical Care Literature over a Period of Ten Years.**

*Christopher A. Paciullo, Pharm.D.,<sup>1</sup> Catherine Kim, Pharm.D. Student,<sup>2</sup> Yannolis Hernandez, Pharm.D. Student,<sup>3</sup> Sandra L. Kane-Gill, Pharm.D., M.S., FCCM, FCCP<sup>4</sup>; (1) Emory University Hospital, Atlanta, GA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (3)Mercer University College of Pharmacy and Health Sciences, Atlanta, GA; (4)University of Pittsburgh School of Pharmacy, Pittsburgh, PA*

**49. Continuous Neuromuscular Blockade and Train-of-Four Monitoring in Patients Treated with Therapeutic Hypothermia.**

*James M. Hollands, Pharm.D., Mollie Gowan, Pharm.D.; Barnes-Jewish Hospital, St. Louis, MO*

**50. Impact of the Propofol Shortage on Patient Outcomes in a Cardiothoracic Surgical Intensive Care Unit.**

*Rachelle Whiteside, Pharm.D., Edward Horn, Pharm.D., BCPS, David Pavlik, Pharm.D., Robert Simpson, Pharm.D., BCPS; Allegheny General Hospital, Pittsburgh, PA*

**51. Evaluating Dosing of Erythropoiesis-Stimulating Agents on Hemoglobin Levels in Bloodless Medicine Patients.**

*Louise-Marie Gillis, Pharm.D., Edward T. Horn, Pharm.D., Robert W. Simpson, Pharm.D.; Allegheny General Hospital, Pittsburgh, PA*

**52. Effect of Home  $\beta$ -Blocker Use in Patients Presenting with Subarachnoid Hemorrhage.**

*Kevin W. McConeghy, Pharm.D.,<sup>1</sup> Eljim P. Tesoro, Pharm.D.,<sup>2</sup> Jeffrey J. Mucksavage, Pharm.D.,<sup>2</sup> Keri S. Kim, Pharm.D.<sup>3</sup>; (1)University of Illinois at Chicago Medical Center, Chicago, IL; (2)University of Illinois at Chicago, Chicago, IL; (3)University of Illinois Medical Center at Chicago, Chicago, IL*

**53. Selective Decontamination in the Cardiovascular Intensive Care Unit: Analysis of the Consumption of Different Groups of Antimicrobial Agents.**

*María de la Paz Pacheco, Senior Pharmacist, Alejandro Santiago, Senior Pharmacist, Miguel Sánchez, Head M.D., Virginia Puebla, Resident, Rocío Manzano, Resident, José A Peña, Resident, Ainhoa Arenaza, Senior Pharmacist, Lourdes Arias, Head Pharm.D.; Hospital Clínico San Carlos, Madrid, Spain*

**54. Impact of a Pharmacist Sedation Program on the Medical and Surgical Mechanically Ventilated Patient Population in a Level II Trauma Center.**

*Lisa Lederhouse, Pharm.D., Mary Beth Bobek, Pharm.D.; New Hanover Regional Medical Center, Wilmington, NC*

**55. Cytochrome P450 Eicosanoid Levels in Cerebrospinal Fluid and Delayed Cerebral Ischemia in Subarachnoid Hemorrhage Patients.**

*Mark K. Donnelly, B.S., Elizabeth Crago, R.N., MSN, Paula Sherwood, R.N., Ph.D., CNRN, Michael Horowitz, M.D., Samuel Poloyac, Pharm.D., Ph.D.; University of Pittsburgh, Pittsburgh, PA*

**56. Improving Adherence to an Intensive Care Unit Sedation Protocol and Effects on Patient Outcomes.**

*Edward D. Leaders, Pharm.D.,<sup>1</sup> Phil E. Grgurich, Pharm.D.,<sup>1</sup> Garret L. Newkirk, Pharm.D.,<sup>1</sup> William J. Peppard, Pharm.D.,<sup>1</sup> Karen Brasel, M.D.<sup>2</sup>; (1)Froedtert Hospital, Milwaukee, WI; (2)Medical College of Wisconsin, Milwaukee, WI*

**57E. Impact of Quetiapine on the Resolution of Individual Delirium Symptoms: An A Priori-Designed Analysis of a Randomized, Double-Blind, Placebo-Controlled Study.**

*John W. Devlin, Pharm.D., FCCP,<sup>1</sup> Yoanna Skrobik, M.D.,<sup>2</sup> Richard Riker, M.D.,<sup>3</sup> Eric Hinderleider, B.S.,<sup>4</sup> Russel J. Roberts, Pharm.D.,<sup>5</sup> Jeffrey J. Fong, Pharm.D., BCPS<sup>6</sup>; (1) Northeastern University, Boston, MA; (2)Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada; (3)Maine Medical Center, Portland, ME; (4)Northeastern University School of Pharmacy, Boston, MA; (5)Tufts Medical Center, Boston, MA; (6)Massachusetts College of Pharmacy and Health Sciences, Worcester, MA*

**58. Comparison of Sodium Acetate and Sodium Chloride on Clinical Outcomes in Patients with Intracranial Injury.**

Ifeoma Asoh, Pharm.D.,<sup>1</sup> Brian S. Smith, Pharm.D., BCPS,<sup>1</sup> Raphael Carandang, M.D.,<sup>1</sup> Jeffrey J. Fong, Pharm.D., BCPS<sup>2</sup>; (1)UMass Memorial Medical Center, Worcester, MA; (2)Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

**Medication Safety**

**165. Implementation of Medication Reconciliation by a Pharmacist in Patients with Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome on Highly Active Antiretroviral Therapy.**

Courtney L. Tam, Pharm.D.,<sup>1</sup> Tomasz Z. Jodlowski, Pharm.D., BCPS (AQ-ID)<sup>2</sup>; (1)Beth Israel Medical Center – Petrie Campus, New York, NY; (2)St. John’s University College of Pharmacy and Allied Health Professions, Queens, NY

**166. Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty: A Meta-analysis.**

Carlos Alves, Pharm.D.,<sup>1</sup> Ana F. Macedo, Pharm.D., Ph.D.,<sup>2</sup> Francisco Batel-Marques, Pharm.D., Ph.D.<sup>3</sup>; (1)CICS – Health Sciences Research Centre, University of Beira Interior; School of Pharmacy, University of Coimbra, Coimbra, Portugal; (2)Central Portugal Regional Pharmacovigilance Unit – AIBILI; CICS – Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal; (3)Central Portugal Regional Pharmacovigilance Unit – AIBILI; School of Pharmacy, University of Coimbra, Coimbra, Portugal

**167. The Role of Computerized Clinical Decision Support in Reducing Inappropriate Medication Administration During Epidural Therapy.**

Jonathon Pouliot, Pharm.D., M.S., Erin Neal, Pharm.D., BCPS; Vanderbilt University Medical Center, Nashville, TN

**168. Compliance with NASPE Monitoring Guidelines for Amiodarone.**

Prudence Hofmann, Pharm.D.,<sup>1</sup> Ola O. Oyeyayo, Pharm.D.,<sup>2</sup> Carrie Rogers, Pharm.D.,<sup>1</sup> Phillip Lubanski, Pharm.D.,<sup>1</sup> Cheryl Holt, Pharm.D.,<sup>1</sup> Tera Moore, Pharm.D.<sup>1</sup>; (1)South Texas Veterans Health Care System, San Antonio, TX; (2)University of Texas at Austin/University of Texas Health Science Center at San Antonio, San Antonio, TX

**171. Identifying and Removing Usage Barriers of Infusion Smart Pumps.**

Holly Herring, Pharm.D., Toni Ripley, Pharm.D., Kevin Farmer, Ph.D.; The University of Oklahoma College of Pharmacy, Oklahoma City, OK

**172E. Evaluation of Risk Factors for Warfarin Resistance Following Administration of Vitamin K.**

Sheri J. VanOsdol, Pharm.D., Heather J. Ipema, Pharm.D., Edith A. Nutescu, Pharm.D.; University of Illinois at Chicago College of Pharmacy, Chicago, IL

**Pediatrics**

**207. Gentamicin Pharmacokinetics in Neonates Undergoing Therapeutic Hypothermia.**

Liana Mark, Pharm.D.,<sup>1</sup> Addishiwot Solomon, Pharm.D.,<sup>2</sup> Frances J. Northington, M.D.,<sup>3</sup> Carlton K.K. Lee, Pharm.D., MPH<sup>4</sup>; (1)The Johns Hopkins Hospital, Baltimore, MD; (2)University of Maryland School of Pharmacy, Baltimore, MD; (3)Department of Pediatrics,

Neuro-intensive Care Nursery, Johns Hopkins University, Baltimore, MD; (4)Department of Pediatrics, Johns Hopkins University & Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD

### **Transplant/Immunology**

#### **258. Evaluation of a Preemptive Strategy for CMV Disease Prevention in Cardiac Transplant Patients.**

*Edward T. Horn, Pharm.D., BCPS,<sup>1</sup> Dana K. Reither, Pharm.D.,<sup>2</sup> Lauren King, Pharm.D.,<sup>3</sup> Stephen H. Bailey, M.D.,<sup>1</sup> Walter E. McGregor, M.D.,<sup>1</sup> Robert J. Moraca, M.D.,<sup>1</sup> George G. Sokos, D.O.,<sup>1</sup> Raymond L. Benza, M.D.,<sup>1</sup> Srinivas Murali, M.D.<sup>1</sup>;* (1)Allegheny General Hospital, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (3)Mylan School of Pharmacy Duquesne University, Pittsburgh, PA

#### **259F. Corticosteroid Withdrawal in Renal Transplant Recipients: An Analysis of the Mycophenolic Acid Observational Renal Transplant Registry.**

*Kimi Ueda Stevenson, Pharm.D., BCPS,<sup>1</sup> Anne Wiland, Pharm.D., BCPS,<sup>2</sup> V. Ram Peddi, M.D.<sup>1</sup>;* (1)California Pacific Medical Center, San Francisco, CA; (2)Novartis Pharmaceutical Corporation, East Hanover, NJ

#### **260. Early Analyses of Renal Transplant Recipients Who Received Expanded Criteria Donor Kidneys from the Mycophenolic Acid Observational Renal Transplant Registry.**

*Kimi Ueda Stevenson, Pharm.D., BCPS,<sup>1</sup> Anne Wiland, Pharm.D., BCPS,<sup>2</sup> V. Ram Peddi, M.D.<sup>1</sup>;* (1)California Pacific Medical Center, San Francisco, CA; (2)Novartis Pharmaceutical Corporation, East Hanover, NJ

#### **261. Comparisons of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil Outcomes from the Mycophenolic Acid Observational Renal Transplant Registry.**

*Ali Olyaei, Pharm.D., BCPS,<sup>1</sup> Anne Wiland, Pharm.D., BCPS,<sup>2</sup> Lonnie Smith, Pharm.D.<sup>3</sup>;* (1)Oregon State University/Oregon Health and Sciences University, Portland, OR; (2) Novartis Pharmaceutical Corporation, East Hanover, NJ; (3)University of Utah Hospitals and Clinics, Salt Lake City, UT

#### **262. African American Renal Transplant 1-Year Outcomes from the Mycophenolic Acid Observational Renal Transplant Registry.**

*Lonnie Smith, Pharm.D.,<sup>1</sup> Anne Wiland, Pharm.D., BCPS,<sup>2</sup> Ali Olyaei, Pharm.D., BCPS<sup>3</sup>;* (1)University of Utah Hospitals and Clinics, Salt Lake City, UT; (2)Novartis Pharmaceutical Corporation, East Hanover, NJ; (3)Oregon State University/Oregon Health and Sciences University, Portland, OR

#### **263E. Steroid-free, Calcineurin Inhibitor Minimizing Regimen with Long-term Mycophenolate Mofetil Monotherapy for HLA Identical Living Donor Kidney Transplantation: Long-term Outcomes.**

*Adele R. Shields, Pharm.D.,<sup>1</sup> Rita R. Alloway, Pharm.D.,<sup>1</sup> Amit Govil, M.D.,<sup>1</sup> Gautham Mogilishetty, M.D.,<sup>1</sup> Michael Cardi, M.D.,<sup>2</sup> Shahzad Safdar, M.D.,<sup>2</sup> Shaoming Huang, M.D.,<sup>2</sup> E. Steve Woodle, M.D.<sup>1</sup>;* (1)University of Cincinnati, Cincinnati, OH; (2)The Christ Hospital, Cincinnati, OH

#### **264. A Prospective, Single-Center, Pilot Study of Pretransplant Thymoglobulin Administration and Early Corticosteroid Withdrawal in Living Donor Renal Transplant Recipients.**

*Adele R. Shields, Pharm.D.,<sup>1</sup> Rita R. Alloway, Pharm.D.,<sup>1</sup> Michael Cardi, M.D.,<sup>2</sup> Shahzad Safdar, M.D.,<sup>2</sup> Shaoming Huang, M.D.,<sup>2</sup> Paul Brailey, Ph.D.,<sup>1</sup> Alin Girnita, Ph.D.,<sup>1</sup> Rino Munda, M.D.,<sup>1</sup> Tonya Dorst, M.A.,<sup>1</sup> E. Steve Woodle, M.D.<sup>1</sup>;* (1)University of Cincinnati, Cincinnati, OH; (2)The Christ Hospital, Cincinnati, OH

**265. Pepper Mould Contamination Risk to Immunocompromised.**

*John D. Cleary, Pharm.D.,<sup>1</sup> Jessica Robinson, Pharm.D.<sup>2</sup>;* (1)University of Mississippi Medical Center, Jackson, MS; (2)University of Charleston School of Pharmacy, Charleston, WV

**266. Use of HMG-CoA Reductase Inhibitors in Liver Transplant Patients with Recurrent Hepatitis C Virus.**

*Sarah E. Yost, Pharm.D.,<sup>1</sup> Heather J. Johnson, Pharm.D.,<sup>2</sup> Kristine S. Schonder, Pharm.D.,<sup>3</sup> Michael DeVera, M.D.,<sup>4</sup> Kapil B. Chopra, M.D.<sup>5</sup>;* (1)University Medical Center, Tucson, AZ; (2)UPMC Department of Pharmacy and Therapeutics, Pittsburgh, PA; (3) University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (4)Loma Linda University Transplantation Institute, Loma Linda, CA; (5)University of Pittsburgh Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Pittsburgh, PA

**268E. Comparison of Calcineurin Inhibitor Administration Post-heart Transplantation.**

*Cory Blacksmith, Pharm.D., Jodie M. Fink, Pharm.D., BCPS,* Cleveland Clinic Foundation, Cleveland, OH

**270. Impact of Immunosuppressant Regimen on the Onset of Hyperlipidemia in Kidney Transplant Recipients.**

*Shelby L. Corman, Pharm.D., M.S., BCPS, Kristine S. Schonder, Pharm.D.;* University of Pittsburgh School of Pharmacy, Pittsburgh, PA

**271. A Single-Center Experience with Conversion Between Two Generic Tacrolimus Formulations.**

*Eric Tichy, Pharm.D., BCPS,<sup>1</sup> Lisa M. McDevitt, Pharm.D., BCPS<sup>2</sup>;* (1)Yale-New Haven Hospital, New Haven, CT; (2)Massachusetts College of Pharmacy and Health Sciences, Boston, MA

**CLINICAL PHARMACY FORUM**

These abstracts describe the delivery, development, justification, or documentation of an innovative clinical pharmacy service; they may be descriptive only and need not contain an evaluative component.

**Adult Medicine**

**274. Evaluation of Medication Reconciliation for Inpatients with Uncontrolled Diabetes: Pre-implementation Study.**

*Charlene A. Hope, Pharm.D., BCPS;* Norwegian American Hospital, Chicago, IL

**275. Evaluation of a Diabetic Ketoacidosis Protocol to Improve Quality and Cost of Care.**

*Nishil P. Patel, Pharm.D., BCPS, Suma Dronavalli, M.D., Ishaq Lat, Pharm.D., BCPS;* University of Chicago Medical Center, Chicago, IL

**276. Argatroban Dosing Evaluation Amongst Medical Patients in a Community Hospital.**

*Janene L. Marshall, Pharm.D.,<sup>1</sup> Jorge Berrios, Pharm.D.,<sup>2</sup> Rita Magnuson, Pharm.D.<sup>3</sup>;* (1) Chicago State University College of Pharmacy, Chicago, IL; (2)Cardinal Health, Houston, TX; (3)Little Company of Mary Hospital and Health Care Centers, Evergreen Park, IL

**277. Tranexamic Acid and Decreased Blood Utilization.**

*Tracy S. Elliott, Pharm.D.*; Cleveland Clinic-Fairview Hospital, Cleveland, OH

**278. Impact of Hospital-Based Pharmacist Advocates in Care Transitions: Identification and Description of Medication Related Interventions After Patient Discharge from Hospital to Home.**

*Rima A. Mohammad, Pharm.D.*,<sup>1</sup> *Jenny J. Kim, Pharm.D.*,<sup>2</sup> *Amy C. Donihi, Pharm.D.*,<sup>1</sup> *Kim Coley, Pharm.D.*<sup>1</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)University of Pittsburgh Medical Center, Pittsburgh, PA

**279. Impact of Inappropriate Vitamin K Use for Management of Elevated International Normalized Ratios on Hospital Length of Stay.**

*Denise M. Kolanczyk, Pharm.D., BCPS*, *Alexander J. Ansara, Pharm.D., BCPS*; Indiana University Health Methodist Hospital, Indianapolis, IN

**Ambulatory Care**

**280. Results of a Pharmacist-Managed Cardiovascular Risk Reduction Clinic at a Veterans Affairs Medical Center.**

*Chabely Rufin, Pharm.D.*, *Elizabeth C. Hamilton, Pharm.D.*, *Crystal J. Wink, Pharm.D.*; *Ralph H. Johnson VA Medical Center, Charleston, SC*

**281. Impact of a Pharmacist-Managed Diabetes Clinic on Glycemic Control Using Concentrated U-500 Regular Insulin.**

*Tzu-Ying (Yasmina) Lee, Pharm.D., BCPS*, *Anthony Firek, M.D.*; VA Loma Linda Health Care System, Loma Linda, CA

**282. A Pharmacist-Run Collaborative Care Program in a Free Urban Primary Care Clinic.**

*Lauren J. Jonkman, Pharm.D., BCPS*,<sup>1</sup> *Sharon E. Connor, Pharm.D.*,<sup>1</sup> *Mary I. Herbert, M.S., MPH*,<sup>2</sup> *Sara Mrvos, Pharm.D. Candidate, 2014*<sup>3</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)UPMC Department of General Internal Medicine, Pittsburgh, PA; (3)Duquesne University Mylan School of Pharmacy, Pittsburgh, PA

**283. Highlighting the Work of the Ambulatory Care PRN in 2011.**

*Marissa E. Quinones, Pharm.D.*,<sup>1</sup> *Renee Koski, Pharm.D., CACP*,<sup>2</sup> *Lea E. dela Pena, Pharm.D., BCPS*,<sup>3</sup> *Matthew Pitlick, Pharm.D., BCPS*,<sup>4</sup> *Sarah M. Westberg, Pharm.D., BCPS*<sup>5</sup>; (1)Parkland, Dallas, TX; (2)Ferris State University College of Pharmacy, Marquette, MI; (3)Midwestern University Chicago College of Pharmacy, Downers Grove, IL; (4)St. Louis College of Pharmacy, St. Louis, MO; (5)University of Minnesota College of Pharmacy, Minneapolis, MN

**284. Role of a Pharmacist in a Patient-Centered Medical Home for University Employees.**

*Erica F. Pearce, Pharm.D.*,<sup>1</sup> *William T. Manard, M.D.*,<sup>2</sup> *Gillian S. Stephens, M.D.*<sup>2</sup>; (1)St. Louis College of Pharmacy, St. Louis, MO; (2)St. Louis University, St. Louis, MO

**285. Reimbursed Medication Therapy Management Services in a Community Health Center for a Medicare Population.**

*Rebekah E. Sherman, Pharm.D., CDE*, *Leslie A. Vitin, Pharm.D., CDE*; Northeastern University, Boston, MA

**286. Pharmacist-Managed Diabetes Service in a Rural Free Clinic.**

*Katherine R. Gerrald, Pharm.D., BCPS, Julie M. Sease, Pharm.D., BCPS, Meg A. Franklin, Pharm.D., Ph.D.; Presbyterian College School of Pharmacy, Clinton, SC*

**287. Collaborative Health Risk Assessment and Management Program Between the University Pharmacy Clinic and City Employees.**

*Krista D. Capehart, Pharm.D., MSPharm, Michael O'Neil, Pharm.D., Michael Bottorff, Pharm.D., FCCP; University of Charleston School of Pharmacy, Charleston, WV*

**288. Development of an Automated Tool to Document Clinic-Based Pharmacists' Activities.**

*Stephen F. Eckel, Pharm.D., MHA, BCPS, Lindsey B. Poppe, Pharm.D., M.S., BCPS, Sarah K. Ford, Pharm.D., BCPS, CPP, Caron P. Misita, Pharm.D., BCPS, CPP, Lauren B. McKnight, Pharm.D., CPP, Sujing Yang, B.S., Ian R. Willoughby, Pharm.D.; University of North Carolina Hospitals, Chapel Hill, NC*

**289. Implementation of a Pharmacist-Led Medication Reconciliation Service in a Federally Qualified Health Center.**

*Marissa C. Salvo, Pharm.D.; University of Connecticut – School of Pharmacy, Storrs, CT*

**290. Incorporating a Clinical Pharmacist on a Medical Team Serving the Homeless.**

*Marissa C. Salvo, Pharm.D.; University of Connecticut – School of Pharmacy, Storrs, CT*

**291. Development of a Medication Therapy Management Service at a Free Clinic.**

*Catherine A. Bourg, Pharm.D., BCPS,<sup>1</sup> Lisa J. Moherman, Pharm.D., CACP,<sup>2</sup> Tara Whetsel, Pharm.D.<sup>3</sup>; (1)University of Georgia College of Pharmacy, Athens, GA; (2)West Virginia University Hospitals, Morgantown, WV; (3)West Virginia University School of Pharmacy, Morgantown, WV*

**Critical Care**

**304. Pseudoephedrine for Neurogenic Shock After Acute Spinal Cord Injury.**

*Jessica L. Johnson, Pharm.D.,<sup>1</sup> G. Christopher Wood, Pharm.D.,<sup>2</sup> Jennifer N. Mitchell, Pharm.D.,<sup>3</sup> Louis J. Magnotti, M.D.,<sup>4</sup> Martin A. Croce, M.D.,<sup>5</sup> Bradley Boucher, Pharm.D.,<sup>2</sup> Joseph M. Swanson, Pharm.D.,<sup>2</sup> Timothy C. Fabian, M.D.<sup>5</sup>; (1)Frederick Memorial Hospital, Frederick, MD; (2)University of Tennessee Health Science Center, Memphis, TN; (3)Veterans Affairs Medical Center, Charleston, SC; (4)University of Tennessee Health Sciences Center, Memphis, TN; (5)University of Tennessee College of Pharmacy, Memphis, TN*

**305. Using Non-bronchoscopic Bronchoalveolar Lavage-Obtained Respiratory Cultures to Guide Antimicrobial Therapy in Patients with Suspected Pneumonia.**

*Kay Lyn Lauer, Pharm.D.,<sup>1</sup> John S. Rinck, RRT,<sup>1</sup> John P. Kepros, M.D.,<sup>2</sup> Curtis L. Smith, Pharm.D.<sup>3</sup>; (1)Sparrow Health System, Lansing, MI; (2)Michigan State University, East Lansing, MI; (3)Ferris State University College of Pharmacy, Lansing, MI*

**306. Optimizing Heparin Dosing in Patients with Cardiac Arrest Undergoing Therapeutic Hypothermia.**

*Jessica C. Carney, Pharm.D.,<sup>1</sup> Randall Absher, Pharm.D.,<sup>1</sup> Tatiana Daniels, Pharm.D.<sup>2</sup>; (1)The Moses H. Cone Memorial Hospital, Greensboro, NC; (2)University of North Carolina, Eshelman School of Pharmacy, Chapel Hill, NC*

**307E. Survey of Heparin-Induced Thrombocytopenia (HIT) Laboratory Testing and Evaluation of a Tailored HIT Screening Protocol Based on the 4Ts Scoring System.**

*Wesly A. Pierce, Pharm.D., Joseph Mazur, Pharm.D., BCPS, BCNSP, Charles S. Greenberg, M.D., John Lazarchick, M.D.; Medical University of South Carolina, Charleston, SC*

**Endocrinology**

**321. Adjunctive Sitagliptin Therapy in Postoperative Cardiac Surgery Patients: A Pilot Study.**

*Marcia L. Brackbill, Pharm.D., BCPS,<sup>1</sup> Ateequr Rahman, Ph.D., MBA,<sup>1</sup> Jeffrey Sandy, R.N.,<sup>2</sup> M. Denton Stam, M.D.,<sup>3</sup> Arthur F. Harralson, Pharm.D., BCPS<sup>1</sup>; (1)Shenandoah University, Bernard J. Dunn School of Pharmacy, Winchester, VA; (2)Winchester Medical Center, Winchester, VA; (3)Valley Health Cardiothoracic and Vascular Surgeons, Winchester, VA*

**Geriatrics**

**325. A Pilot Fee-for-Service Medication Therapy Management Program in a Geriatric Primary Care Clinic.**

*Sunny A. Linnebur, Pharm.D., FCCP,<sup>1</sup> Joseph P. Vande Griend, Pharm.D.,<sup>1</sup> Gina Moore, Pharm.D., MBA,<sup>1</sup> Irene Girgis, Pharm.D.<sup>2</sup>; (1)University of Colorado School of Pharmacy, Aurora, CO; (2)Colorado Access, Denver, CO*

**Medication Safety**

**336. Interdisciplinary Approach to Medication Safety: Collaborative Care for Developmentally Disabled Individuals.**

*Philip Rolland, Pharm.D., MHA; Mexia State Supported Living Center, Mexia, TX*

**337E. Investigation of Potential Neurological Effects of Stabilizers Used in Immunoglobulin Products: Comparison of Proline and Glycine.**

*Martin O. Spycher, Ph.D.,<sup>1</sup> Gerhard Dickneite, Ph.D.<sup>2</sup>; (1)CSL Behring AG, Switzerland; (2)CSL Behring GmbH, Marburg, Germany*

**338E. An Analysis of Medication Errors Associated with the Use of Technology.**

*Jennifer Phillips, Pharm.D., BCPS,<sup>1</sup> Bonnie Bachenheimer, Pharm.D.,<sup>2</sup> Christopher Kutza, Pharm.D.<sup>2</sup>; (1)Midwestern University, Downers Grove, IL; (2)Advocate Lutheran General Hospital, Park Ridge, IL*

**STUDENT SUBMISSIONS**

These papers describe original research by students in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, and pharmacogenomics in which the research effort is ongoing.

**ADR/Drug Interactions**

**388. A Description of Antibiotic-Related Laboratory Interferences.**

*Thomas J. Wolfel, B.S., Biological, Sciences, Pharm.D. Candidate, 2012,<sup>1</sup> Sandra Kane-Gill, Pharm.D., M.S., FCCM,<sup>1</sup> Pamela Smithburger, Pharm.D.,<sup>2</sup> Megan D. Schultz, Pharm.D. Candidate, 2012,<sup>1</sup> Cortlynn Latsha, Pharm.D. Candidate, 2012,<sup>1</sup> Lauren M. Fisher, Pharm.D.*

---

Candidate, 2012,<sup>1</sup> Ashley N. Hogue, Pharm.D. Candidate, 2012<sup>1</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)UPMC Presbyterian, Pittsburgh, PA

### **Ambulatory Care**

**389. Assessing Interest in Clinical Pharmacy Services Within a Unique Community Setting.**  
*Nadine H. Kazem, M.A., Pharm.D. Candidate, Samantha Karr, Pharm.D., BCPS, Mary K. Gurney, Ph.D., R.Ph.;* Midwestern University College of Pharmacy, Glendale, AZ

**390. Identified Drug Therapy Problems in a Federally Qualified Health Center.**  
*Riane J. Ghamrawi, Pharm.D. Candidate, Natalie J. Kolehmainen, Pharm.D. Candidate, Eric M. Tuttle, Pharm.D. Candidate, Magdi H. Awad, Pharm.D.;* Northeast Ohio Medical University, Rootstown, OH

**391. Patients' Perception of Clinical Pharmacy Services in a Federally Qualified Health Center.**  
*Natalie J. Kolehmainen, Pharm.D. Candidate, Riane J. Ghamrawi, Pharm.D. Candidate, Eric M. Tuttle, Pharm.D. Candidate, Magdi H. Awad, Pharm.D.;* Northeast Ohio Medical University, Rootstown, OH

**392. Utilization of iPads to Facilitate Data Collection During Pediatric Screening Events.**  
*Amy E. Haver, Pharm.D. Candidate,<sup>1</sup> Nicole Marcotullio, Pharm.D.,<sup>2</sup> Jennifer P. Elliott, Pharm.D.<sup>1</sup>;* (1)Duquesne University Mylan School of Pharmacy, Pittsburgh, PA; (2) Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA

**393. Risk for Medication Non-adherence and Other Drug Therapy Problems Among Ambulatory Patients in a Safety-Net Health-System.**  
*Amanda Skibowski, Pharm.D. Candidate, 2014,<sup>1</sup> Alan J. Zillich, Pharm.D.,<sup>1</sup> Bradley N. Doebbeling, M.D., M.S.,<sup>2</sup> Margie E. Snyder, Pharm.D., MPH<sup>1</sup>;* (1)Purdue University College of Pharmacy, West Lafayette, IN; (2)Indiana University School of Medicine, Indianapolis, IN

### **Cardiovascular**

**394. A Comparison of Survey Methods on Vitamin, Herbal, and Over-the-Counter Product Use in Patients with Heart Failure.**  
*Anita Kashyap, Pharm.D. Candidate,<sup>1</sup> Stuart L. Burke, Pharm.D. Candidate,<sup>1</sup> Lucas M. Boehm, Pharm.D. Candidate,<sup>1</sup> Leah Holschbach, Pharm.D., B.S.,<sup>2</sup> Tim M. Miller, Pharm.D.,<sup>1</sup> Orly Vardeny, Pharm.D., M.S.<sup>1</sup>;* (1)University of Wisconsin School of Pharmacy, Madison, WI; (2)Froedtert Hospital, Milwaukee, WI

**395. Inpatient Management of Warfarin Therapy by Pharmacists Compared to Physicians.**  
*Pio Juan Lansangan, B.S.,<sup>1</sup> Jin-Hee Nomura, Pharm.D.,<sup>2</sup> Teresa Hong, Pharm.D.,<sup>2</sup> Lynn Ishida-Kitazawa, Pharm.D.,<sup>2</sup> Sheryl L. Chow, Pharm.D., BCPS<sup>3</sup>;* (1)Western University of Health Sciences, Pomona, CA; (2)Centinela Hospital Medical Center, Inglewood, CA; (3) Western University of Health Sciences and LA BioMed at Harbor-UCLA, Pomona, CA

### Clinical Administration

**396. Analysis of Wait Time Disparities in the Emergency Department for Patients Reporting with a Chief Complaint of Chest Pain from 2003 to 2008.**

*Melissa Buchanan, B.S., Tina Tseng, Ph.D., MSPH; Campbell University College of Pharmacy & Health Sciences, Buies Creek, NC*

**397. A Mentoring Program for Clinical and Operation Supervisors.**

*Kayley M. Lyons, Pharm.D. Student,<sup>1</sup> Steve Bohn, R.Ph.,<sup>2</sup> Ann Nadrash, Pharm.D., BCPS<sup>2</sup>; (1)South Dakota State University College of Pharmacy, Sioux Falls, SD; (2)Kaiser Permanente Colorado Region, Aurora, CO*

**398. Developing a Senti7®-Driven Inpatient Clinical Pharmacy Service.**

*Jennifer Popa, Pharm.D. Candidate, Andrew P. Smith, Pharm.D. Candidate, Christina J. Dewar, Pharm.D., BCPS; Aultman Hospital Inpatient Pharmacy, Canton, OH*

### Community Pharmacy Practice

**399. Improving Health Outcomes and Continuity of Care in Underserved, Urban Populations.**

*Katie Park, Pharm.D. Candidate, Jamie L. McConaha, Pharm.D.; Duquesne University Mylan School of Pharmacy, Pittsburgh, PA*

**400. Financial Impact of a Community Pharmacy–Based Anticoagulation Service.**

*Nicholas P. Mariani, none; Wayne State University, Tecumseh, Ontario, Canada*

### Critical Care

**401. Assessing an Institution-Specific Therapeutic Hypothermia Protocol: Outcomes and Associated Adverse Events.**

*Sara Varnado, Pharm.D. Candidate, Lam Nguyen, Pharm.D., Robert MacLaren, Pharm.D.; University of Colorado School of Pharmacy, Aurora, CO*

**402. Observational Study of Dexmedetomidine in Trauma Critical Care Patients.**

*Kristina Rokas, Pharm.D. Candidate,<sup>1</sup> April D. Miller, Pharm.D., BCPS,<sup>1</sup> Brienne L. Dunn, Pharm.D.,<sup>1</sup> Christopher Watson, M.D.,<sup>2</sup>; (1)South Carolina College of Pharmacy – USC, Columbia, SC; (2)Palmetto Health Richland, Columbia, SC*

**403. A Multicenter Characterization of Antipsychotic Use for the Treatment of Delirium in Medical ICU Patients.**

*Allison Meyer, Pharm.D. Candidate,<sup>1</sup> April D. Miller, Pharm.D., BCPS,<sup>1</sup> Emily K. Dornblaser, Pharm.D., BCPS,<sup>2</sup> Cassandra J. Bellamy, Pharm.D., BCPS,<sup>3</sup> William D. Schweickert, M.D.,<sup>3</sup> Amanda M. Ball, Pharm.D., BCPS<sup>3</sup>; (1)South Carolina College of Pharmacy – USC Campus, Columbia, SC; (2)University of New England, Portland, ME; (3)Hospital of the University of Pennsylvania, Philadelphia, PA*

**404. Hemodynamic Targets and Vasopressor Use in Neurogenic Shock.**

*Maryjoy R. Lepak, Pharm.D. Candidate,<sup>1</sup> April D. Miller, Pharm.D., BCPS,<sup>1</sup> Kimberly B. Clark, Pharm.D., BCPS<sup>2</sup>; (1)South Carolina College of Pharmacy – USC Campus, Columbia, SC; (2)Greenville Hospital System University Medical Center, Greenville, SC*

**405. A Retrospective Cohort Study on the Use of Dexmedetomidine in Patients with Traumatic Brain Injury.**

*Jacquelyn E. Bryant, Pharm.D. Candidate,<sup>1</sup> April D. Miller, Pharm.D., BCPS,<sup>1</sup> Brienne L. Dunn, Pharm.D.,<sup>1</sup> Christopher M. Watson, M.D.<sup>2</sup>;* (1)South Carolina College of Pharmacy – USC, Columbia, SC; (2)Palmetto Health Richland, Columbia, SC

**Education/Training****406. Evaluation of an Interprofessional Approach to Teaching Medication Therapy Management (MTM).**

*Jaelyn Kruse, Pharm.D. Candidate, Jaelyn A. Kruse, Pharm.D. Candidate, M.S., B.S.,<sup>1</sup> Zachary N. Jenkins, Pharm.D. Candidate,<sup>2</sup> Austin Fredrickson, M.D. Candidate,<sup>3</sup> Timothy R. Ulbrich, Pharm.D.,<sup>3</sup> Stacey R. Schneider, Pharm.D.<sup>3</sup>;* (1)Northeast Ohio Medical University, Willowick, OH; (2)Northeast Ohio Medical University, Akron, OH; (3)Northeast Ohio Medical University, OH

**407. Assessing Older Adults' Knowledge of Safe Medication Use and Practices.**

*Samantha M. Boudreau, Pharm.D. Candidate, 2013, Helen Pervanas, Pharm.D.;* Massachusetts College of Pharmacy and Health Sciences – Worcester/Manchester, Worcester, MA

**408. Assessment of Student Pharmacist Learning from a Multidisciplinary Older Adult Home Visit.**

*Teresa M. Breslin III, Pharm.D. Candidate,<sup>1</sup> Alexander J. Kulik III, Pharm.D. Candidate,<sup>1</sup> Carol A. Bugalski Stutrud, B.S.,<sup>1</sup> Cassandra J. Bowers, Ph.D.,<sup>2</sup> GERALYNN B. SMITH, M.S.,<sup>1</sup> Jennifer Mendez, Ph.D.,<sup>3</sup> Nelia M. Afonso, M.D.,<sup>4</sup> Cheryl C. Waites, Ed.D.,<sup>2</sup> Mary Beth O'Connell, Pharm.D.<sup>1</sup>;* (1)Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI; (2)Wayne State University, College of Social Work, Detroit, MI; (3)Wayne State University, School of Medicine, Detroit, MI; (4) Oakland University William Beaumont School of Medicine, Rochester, MI

**409. North Carolina Pharmacists' Practices and Opinions of Smoking Cessation Counseling.**

*Janna L. Currie, Pharm.D./MSCR Candidate, Nathan J. Hudson, Pharm.D./MSCR Candidate, Wesley D. Rich, Ph.D.;* Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC

**410. Experiential Value of an Older Adult Medication Assessment Early in the Pharmacy Curriculum.**

*Kimberly M. Rutkowski, Pharm.D. Student, Kirsten M. Freitel, Pharm.D. Student, Tara C. Rosenthal, Pharm.D. Student, GERALYNN B. SMITH, M.S., Mary Beth O'Connell, Pharm.D.;* Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI

**411. Building a Curriculum to Combat Obesity in Elementary Schools.**

*Chelsea M. Harrison, Pharm.D. Candidate, Elizabeth J. Bunk, Pharm.D. Candidate, Ashley D. Modany, Pharm.D. Candidate, Jennifer P. Elliott, Pharm.D., Nicole Marcotullio, Pharm.D.;* Duquesne University Mylan School of Pharmacy, Pittsburgh, PA

**412. Impact of Community Pharmacy Experience in a Family Medicine Residency.**

*Sarah E. Krahe Dombrowski, B.S.,<sup>1</sup> Roberta Farrah, Pharm.D., BCPS,<sup>2</sup> Stephanie Harriman McGrath, Pharm.D.<sup>3</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2) UPMC St. Margaret Hospital, Pittsburgh, PA; (3)Rite Aid Pharmacy, Pittsburgh, PA*

**413. Impact of a Student-Implemented Patient Education Campaign.**

*Alexa M. Sevin, Pharm.D. Candidate, Marshall D. Stewart, Pharm.D. Candidate, Kyle Hampson, Pharm.D. Candidate, Pamela H. Koerner, Pharm.D., B.S., Jennifer P. Elliot, Pharm.D.; Duquesne University, Pittsburgh, PA*

**414. Becoming an Author During Your Residency: Pharmacy Resident Publication Rates and Trends (2005-2010).**

*Ashley H. Cribb, Pharm.D. Student, Kalen B. Manasco, Pharm.D., BCPS, AE-C; University of Georgia College of Pharmacy, Augusta, GA*

**415. Gender Disparities in Authorship of Original Research Publications in Pharmacy Journals.**

*Sloan M. Regen, Pharm.D. Candidate,<sup>1</sup> Susannah E. Moroney, Pharm.D., M.S.,<sup>2</sup> Katie J. Suda, Pharm.D., M.S.<sup>1</sup>; (1)University of Tennessee Health Science Center, College of Pharmacy, Memphis, TN; (2)Pfizer Global Medical, Madison, WI*

**416. Student College of Clinical Pharmacy Provides Community Service for the Akron Area Agency on Aging.**

*Christina McKenzie, Pharm.D. Candidate,<sup>1</sup> Natalie Kolehmainen, Pharm.D. Candidate,<sup>1</sup> David Shifrin, Pharm.D. Candidate,<sup>1</sup> Susan M. Fosnight, R.Ph., BCPS, CGP,<sup>2</sup> Patrick J. Gallegos, Pharm.D., BCPS<sup>1</sup>; (1)Northeast Ohio Medical University (formerly known as NEOUCOM), Rootstown, OH; (2)Summa Health System, Akron, OH*

**Emergency Medicine**

**417. Insulin-Based Glucose Control Audit for Emergency Department Observation Unit Patients.**

*Joo Hyun Ha, M.S., B.S.,<sup>1</sup> Miles Hawley, M.D.,<sup>2</sup> Mary Beth Shirk, Pharm.D., B.S.<sup>1</sup>; (1) The Ohio State University Medical Center, Columbus, OH; (2)The Ohio State University, Columbus, OH*

**Endocrinology**

**418. Glucose Control in Cardiac Surgery Patients Following IV Insulin Discontinuation.**

*Elyse R. Weitzman, B.S., Amy C. Donihi, Pharm.D.; University of Pittsburgh School of Pharmacy, Pittsburgh, PA*

**419. The Effects of Adding Liraglutide to an Urban Type 2 Diabetic Population.**

*Milan Sharma, Pharm.D. Candidate,<sup>1</sup> Patrick Healy, R.D., MPH, CDE,<sup>2</sup> Mark Drews, M.D.,<sup>2</sup> Michelle Jacobs, Pharm.D., CDE<sup>1</sup>; (1)Northeastern University Bouve College of Health Sciences, School of Pharmacy, Boston, MA; (2)Whittier Street Health Center, Roxbury, MA*

**Family Medicine**

**420. Evaluation of Statin Therapy in Patients over 40 Years Old with Diabetes Mellitus in a Family Medicine Residency Setting.**

*Samantha M. Allen, Pharm.D. Candidate, 2012,*<sup>1</sup> Roberta Farrah, Pharm.D., BCPS,<sup>2</sup> Sandra C. Sauereisen, M.D.<sup>3</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)UPMC St. Margaret Hospital, Pittsburgh, PA; (3)UPMC St. Margaret's, Pittsburgh, PA

**421. Evaluation of CHF Patients Not Prescribed an ACE/ARB in a Family Medicine Residency Setting.**

*Anne M. Butera, Pharm.D. Candidate, B.S.,*<sup>1</sup> Roberta M. Farrah, Pharm.D.<sup>2</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)UPMC St. Margaret Lawrenceville Family Medical Center, Pittsburgh, PA

**Geriatrics**

**422. Impact of a Pharmacist as a Member of an Interprofessional Team to Identify and Reduce Medication-Related Problems During Transitions of Care from Skilled Nursing Facilities (SNFs) to Home.**

*Karen Soong, Pharm.D. Candidate,*<sup>1</sup> Daniel A. Zlokas, Pharm.D. Candidate,<sup>1</sup> Shachi Tyagi, M.D.,<sup>2</sup> Denise Z. Hodes, MSW,<sup>2</sup> Amelia Gennari, M.D.,<sup>2</sup> Christine M. Ruby, Pharm.D., FASCP, BCPS<sup>1</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)UPMC Shadyside Hospital, Pittsburgh, PA

**423. Classifications of Drug-Related Problems Discovered During Senior Brown Bag Medication Reviews.**

*Ashley M. Tocco, Pharm.D. Student,*<sup>1</sup> Feng Chang, Pharm.D.,<sup>2</sup> Megan E. Kleinow, Pharm.D.,<sup>3</sup> Jamie M. Hwang, Pharm.D.,<sup>4</sup> Candice L. Garwood, Pharm.D.,<sup>1</sup> Hanan S. Khreizat, Pharm.D.,<sup>3</sup> Mary Beth O'Connell, Pharm.D.<sup>1</sup>; (1)Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI; (2)University of Waterloo, School of Pharmacy, Waterloo, Ontario, Canada; (3)Henry Ford Health System, Detroit, MI; (4)Henry Ford Piersen Clinic, Grosse Pointe Farms, MI

**424. Evaluation of Patient Education on Preventive Health Measures and Poison Control Center Awareness During Senior Brown Bag Medication Reviews.**

*Nishi S. Gupta, B.S.(Hons),*<sup>1</sup> Feng Chang, Pharm.D.,<sup>1</sup> Megan E. Kleinow, Pharm.D.,<sup>2</sup> Jamie M. Hwang, Pharm.D.,<sup>3</sup> Candice L. Garwood, Pharm.D.,<sup>4</sup> Hanan S. Khreizat, Pharm.D.,<sup>2</sup> Mary Beth O'Connell, Pharm.D.<sup>4</sup>; (1)University of Waterloo, School of Pharmacy, Waterloo, Ontario, Canada; (2)Henry Ford Health System, Detroit, MI; (3)Henry Ford Piersen Clinic, Grosse Pointe Farms, MI; (4)Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI

**425. Patient Satisfaction and Self-Perceived Knowledge Gained During Senior Brown Bag Medication Reviews.**

*Nishi S. Gupta, B.S.(Hons),*<sup>1</sup> Feng Chang, Pharm.D.,<sup>1</sup> Megan E. Kleinow, Pharm.D.,<sup>2</sup> Jamie M. Hwang, Pharm.D.,<sup>3</sup> Candice L. Garwood, Pharm.D.,<sup>4</sup> Hanan S. Khreizat, Pharm.D.,<sup>2</sup> Mary Beth O'Connell, Pharm.D.<sup>4</sup>; (1)University of Waterloo, School of Pharmacy, Waterloo, Ontario, Canada; (2)Henry Ford Health System, Detroit, MI; (3)Henry Ford Piersen Clinic, Grosse Pointe Farms, MI; (4)Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI

## Health Services Research

### 426. Evaluation of Smoking Rates and Nicotine Dependence Within Sullivan University System.

*Carrie M. Armstrong, Pharm.D. Candidate, MBA,<sup>1</sup> James D. Nash, Pharm.D., MPH, BCPS, CGP,<sup>1</sup> Carolyn W. Chou, Pharm.D.,<sup>2</sup> Megan E. Rose, Pharm.D.<sup>1</sup>; (1)Sullivan University College of Pharmacy, Louisville, KY; (2)Pfizer, Inc, Louisville, KY*

## Hematology/Anticoagulation

### 427. Identification of Reasons for Discontinuation of Dabigatran in an Outpatient Cardiology Office.

*Ruth Seiffert, Pharm.D. Candidate,<sup>1</sup> Bethany E. Helms, Pharm.D.,<sup>1</sup> Linda Snyder, MSN, CRNP,<sup>1</sup> David S. Schwartzman, M.D.,<sup>2</sup> Deanne L. Hall, Pharm.D.<sup>3</sup>; (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh, Pittsburgh, PA; (3)University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center, Pittsburgh, PA*

## Herbal/Complementary Medicine

### 428. Ethnopharmacology Comparison Nicaragua and Peru.

*Anna Bondar, Student;* University of Pittsburgh, Pittsburgh, PA

## HIV/AIDS

### 429. An Apparent Drug Interaction Between Warfarin and the Antiretroviral TRIO Regimen.

*Amulya Vanguri, Pharm.D. Candidate,* Michelle D. Liedtke, Pharm.D., BCPS, R. Chris Rathbun, Pharm.D., BCPS; University of Oklahoma College of Pharmacy, Oklahoma City, OK

## Infectious Diseases

### 430. Do Differences Between Quantitative Viral Plaque Assays Explain Variability Among Pre-clinical Respiratory Syncytial Virus Studies in Animals?

*Indrani Kar, Pharm.D. Candidate, 2013,* Jacob G. Orend, B.S., Kerry M. Empey, Pharm.D., Ph.D.; University of Pittsburgh School of Pharmacy, Pittsburgh, PA

### 431. Adverse Drug Events Secondary to Sulfamethoxazole/Trimethoprim in HIV-Infected Hospitalized Patients.

*Caitlin L. Shamroe, Pharm.D. Candidate,<sup>1</sup> P. Brandon Bookstaver, Pharm.D., BCPS (AQ-ID), AAHIVE,<sup>1</sup> Celeste N. Rudisill, Pharm.D.,<sup>1</sup> Robert R. Moran, Ph.D.<sup>2</sup>; (1)South Carolina College of Pharmacy – USC Campus, Columbia, SC; (2)Health Sciences Research Core – University of South Carolina, Columbia, SC*

### 432. Management of *Stenotrophomonas maltophilia* in Pediatric Patients: A Retrospective Evaluation.

*Ashley E. Jones, Pharm.D. Candidate,* Kalen B. Porter, Pharm.D., BCPS, AE-C; University of Georgia College of Pharmacy, Augusta, GA

### 433. Vancomycin in Combination with Nafcillin Demonstrates Synergy Against Heteroresistant Vancomycin-Intermediate *Staphylococcus aureus* (hVISA).

*Amy Suen, B.S.,* Samira M. Garonzik, Pharm.D., Brian T. Tsuji, Pharm.D.; Laboratory for Antimicrobial Pharmacodynamics University at Buffalo, State University of New York, Buffalo, NY

**434. The Hsp40 Co-chaperone Jj1 is a Negative Regulator of Fluconazole Resistance in *Candida glabrata*.**

*Sarah G. Whaley, B.S., Kelly E. Caudle, Pharm.D., Ph.D., Katherine S. Barker, Ph.D., P. David Rogers, Pharm.D., Ph.D.; University of Tennessee College of Pharmacy, Memphis, TN*

**Medication Safety****435. Identifying Optimal Dosages of Drugs Requiring Weight-Based Calculations in Over- and Underweight Populations.**

*Nicholas P. Wytiaz, Pharm.D. (c),<sup>1</sup> Sandra L. Kane-Gill, Pharm.D., M.S., FCCM, FCCP,<sup>1</sup> Mitchell S. Buckley, Pharm.D.,<sup>2</sup> Lisa M. Thompson, Pharm.D.,<sup>2</sup> Kristina Muzykovsky, Pharm.D.,<sup>3</sup> Henry Cohen, Pharm.D., M.S., FCCM, BCPP, CGP,<sup>3</sup> Amy L. Seybert, Pharm.D.<sup>1</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)St. Joseph's Hospital and Medical Center, Phoenix, AZ; (3)Kingsbrook Jewish Medical Center, Brooklyn, NY*

**436. Simvastatin Safety Pharmacist Intervention Study.**

*Katherine M. Crabb, Pharm.D. Candidate,<sup>1</sup> Marion Wofford, M.D., MPH,<sup>2</sup> Daniel M. Riche, Pharm.D., BCPS, CDE<sup>3</sup>; (1)The University of Mississippi School of Pharmacy, Jackson, MS; (2)University of Mississippi Medical Center, Jackson, MS; (3)The University of Mississippi Schools of Pharmacy and Medicine, Jackson, MS*

**437. Development of a Student Pharmacist-Driven Medication Reconciliation Discharge Program.**

*Peter M. Sullivan, Student, Pharmacist, Amy Jurek, Student Pharmacist; Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA*

**438. Post-FDA Safety Statement Medication Use Evaluation of Rosiglitazone.**

*Keri L. Mills, Pharm.D. Candidate,<sup>1</sup> Marion Wofford, M.D., MPH,<sup>2</sup> Daniel M. Riche, Pharm.D., BCPS, CDE<sup>3</sup>; (1)University of Mississippi School of Pharmacy, Oxford, MS; (2)University of Mississippi Medical Center, Jackson, MS; (3)University of Mississippi School of Pharmacy, Jackson, MS*

**Men's Health****439. Lack of Association Between Statin Therapy and Testosterone Deficiency.**

*Corey L. McEwen, Pharm.D. Candidate,<sup>1</sup> Marion Wofford, M.D., MPH,<sup>2</sup> Daniel M. Riche, Pharm.D., BCPS, CDE<sup>3</sup>; (1)The University of Mississippi School of Pharmacy, Jackson, MS; (2)University of Mississippi Medical Center, Jackson, MS; (3)University of Mississippi School of Pharmacy, Jackson, MS*

**Nephrology****440F. Differential Effect of IV Iron Compounds on Intracellular Reactive Oxygen Species (ROS) Generation in Aortic Coronary Endothelial Cells.**

*Heena V. Patel, Pharm.D. Candidate, Alex J. Prokopienko, Pharm.D. Candidate, Nancy Gertzberg, A.S., Paul Neumann, A.S., Arnie Johnson, Ph.D., Amy Barton Pai, B.S., Pharm.D., BCPS; Albany College of Pharmacy and Health Sciences, Albany, NY*

**441. Management of Serum Calcium and Phosphorous Levels for the Prevention of Mineral Bone Disease in Chronic Kidney Disease Patients on Dialysis by Multidisciplinary Team Care.**

*Da-Hae Jun, B.S.,<sup>1</sup> Na Young Han, M.S.,<sup>1</sup> Eun Hee Ji, Ph.D.,<sup>1</sup> Hyoyoung Park, M.S.,<sup>1</sup> Suhnggwon Kim, M.D., Ph.D.,<sup>2</sup> Jin Suk Han, M.D., Ph.D.,<sup>2</sup> Curie Ahn, M.D., Ph.D.,<sup>2</sup> Yon Su Kim, M.D., Ph.D.,<sup>2</sup> Kwon Wook Joo, M.D., Ph.D.,<sup>2</sup> Kook-Hwan Oh, M.D., Ph.D.,<sup>2</sup> Dong Ki Kim, M.D.,<sup>2</sup> HyunAh Kim, Pharm.D.,<sup>1</sup> Wan Gyoon Shin, Pharm.D., Ph.D.,<sup>1</sup> Hye Suk Lee, M.S.,<sup>3</sup> Jung Mi Oh, Pharm.D.<sup>1</sup>; (1)College of Pharmacy, Seoul National University, Seoul, South Korea; (2)Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; (3)Department of Pharmacy, Seoul National University Hospital, Seoul, South Korea*

**442. Knowledge, Perceptions and Adherence of ESRD Patients Receiving Erythropoietic Therapy and Anemia Management: A Student Pharmacist–Based Survey in an Outpatient Peritoneal Dialysis Clinic.**

*Karen Nenzo, Pharm.D. Candidate,<sup>1</sup> Shailly Shah, Pharm.D. Candidate,<sup>1</sup> Oriyomi Alimi, Pharm.D. Candidate,<sup>1</sup> Iris Hayes, LSW,<sup>2</sup> Carol Dacko, R.N.,<sup>2</sup> Filitsa Bender, M.D.,<sup>3</sup> Thomas Nolin, Pharm.D., Ph.D.<sup>1</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2) DCI, Inc, Pittsburgh, PA; (3)University of Pittsburgh School of Medicine, Pittsburgh, PA*

**Neurology**

**443. Medications Associated with Delirium in Hospitalized Subjects.**

*Caroline A. Lindsay, B.S.,<sup>1</sup> Keiko A. Fukuda, B.A.,<sup>2</sup> S. Andrew Josephson, M.D.,<sup>3</sup> Vanja Douglas, M.D.<sup>3</sup>; (1)University of California–San Francisco, School of Pharmacy, San Francisco, CA; (2)University of California–San Francisco, Department of Neurology, Stroke Sciences Group, San Francisco, CA; (3)University of California–San Francisco, Department of Neurology, San Francisco, CA*

**444. Treatment of Fever During the Acute Stroke Period at a Primary Stroke Center.**

*Ashley H. Cribb, Pharm.D. Student,<sup>1</sup> Diana K. Houng, Pharm.D.,<sup>1</sup> Jody L. Rocker, Pharm.D.,<sup>2</sup> Jeffrey Switzer, D.O.,<sup>2</sup> David Hess, M.D.,<sup>2</sup> Susan C. Fagan, Pharm.D.<sup>3</sup>; (1)University of Georgia College of Pharmacy, Augusta, GA; (2)Georgia Health Sciences University, Augusta, GA; (3)Program in Clinical and Experimental Therapeutics University of Georgia College of Pharmacy Charlie Norwood VA Medical Center Au, Augusta, GA*

**Oncology**

**445. Effects of Mobilization Regimens on the Incidence of Tumor Cell Contamination of the Hematopoietic Stem Cells in Breast Cancer Patients Undergoing Peripheral Blood Stem Cell Transplantation.**

*Sora Choi, B.S., Meghana V. Trivedi, Pharm.D., Ph.D.; University of Houston College of Pharmacy, Houston, TX*

**446. Acneiform Rash Does Not Predict Response to Neoadjuvant Lapatinib Monotherapy in Breast Cancer Patients.**

*Jennifer M. Parma, B.S.,<sup>1</sup> Anne C. Pavlick, B.S.,<sup>2</sup> Jenny C.N. Chang, MBBCh,<sup>2</sup> Mothaffar F. Rimawi, M.D.,<sup>2</sup> Meghana V. Trivedi, Pharm.D., Ph.D.<sup>1</sup>; (1)University of Houston College of Pharmacy, Houston, TX; (2)Baylor College of Medicine, Houston, TX*

**447. Effectiveness of Palonosetron Compared with the Other Serotonin Antagonists in Combination with Aprepitant in Preventing Highly Emetogenic Chemotherapy-Induced Emesis.**

*Boyoon Choi, Ph.D. Candidate,<sup>1</sup> Dong Eun Lee, B.S.,<sup>1</sup> Kyung Im Kim, Ph.D. Candidate,<sup>1</sup>*

Hye Suk Lee, M.S.,<sup>2</sup> Hyunah Kim, Pharm.D.,<sup>1</sup> Wan Gyoon Shin, Pharm.D., Ph.D.,<sup>1</sup> Jung Mi Oh, Pharm.D.<sup>1</sup>; (1)College of Pharmacy, Seoul National University, Seoul, South Korea; (2)Department of Pharmacy, Seoul National University Hospital, Seoul, South Korea

**448. Evaluation of Obesity on Achieving Remission Following Induction Therapy for Acute Myelogenous Leukemia.**

*Laura Leigh Stoudenmire, Pharm.D. Candidate,<sup>1</sup> Morgan Trepte, Pharm.D. Candidate,<sup>1</sup> Katerina Katsanevas, Pharm.D.,<sup>1</sup> Courtney McCracken, M.S. Candidate,<sup>2</sup> David L. DeRemer, Pharm.D., BCOP<sup>1</sup>;* (1)University of Georgia College of Pharmacy and Georgia Health Sciences Health System, Augusta, GA; (2)Georgia Health Sciences University Department of Statistics, Augusta, GA

**Other**

**449. Pharmacists' Role in Evaluation of "As-Necessary" Medications at a Community Hospital.**

*Christine E. Puschak, Pharm.D. Candidate, Jill A. Rebuck, Pharm.D., FCCP, FCCM, BCPS;* Lancaster General Health, Lancaster, PA

**450F. Angiogenic and Vasculoprotective Potential of Angiotensin Receptor Antagonists in the Brain.**

*Lydia Cronic, B.S.,<sup>1</sup> Sahar Soliman, B.S.,<sup>2</sup> Azza El-Remessy, Ph.D.,<sup>2</sup> Susan C. Fagan, Pharm.D.<sup>3</sup>;* (1)University of Georgia College of Pharmacy, Augusta, GA; (2)University of Georgia College of Pharmacy, Veterans Affairs Medical Center, Augusta, GA; (3)Program in Clinical and Experimental Therapeutics University of Georgia College of Pharmacy Charlie Norwood VA Medical Center, Augusta, GA

**451. Evaluation of a Potassium Replacement Protocol in Non-ICU Patients at an Urban Safety Net Hospital.**

*Megan E. Austin, Pharm.D. Candidate,<sup>1</sup> Andrew Smith, Pharm.D.,<sup>2</sup> Tony Huke, Pharm.D.<sup>1</sup>;* (1)Truman Medical Center, Kansas City, MO; (2)UMKC School of Pharmacy, Kansas City, MO

**452. Assessment of Recommendations Made by a Clinical Pharmacist in a Palliative Care Setting: A Retrospective Cohort Study.**

*Holly L. Tumlin, Pharm.D. Candidate;* LeAnn B. Norris, Pharm.D.; South Carolina College of Pharmacy – USC Campus, Columbia, SC

**Pediatrics**

**453. Buprenorphine Withdrawal in an Infant After Cessation of Breastfeeding: A Case Report and Review of the Literature.**

*Hani Elladki, Pharm.D. Candidate,<sup>1</sup> Paul Thill, Pharm.D., BCPS<sup>2</sup>;* (1)Ferris State University, Dearborn Heights, MI; (2)Ferris State University College of Pharmacy, Saginaw, MI

**454. Evaluation of Busulfan-Targeted Therapy and Pharmacokinetics in Pediatric Patients Undergoing Hematopoietic Cell Transplantation.**

*Shirley Yan, B.S., Christopher C. Dvorak, M.D., Lisa Musick, Pharm.D., Jason Law, M.D., Morton J. Cowan, M.D., Biljana Horn, M.D., Janel R. Long-Boyle, Pharm.D., Ph.D.;* University of California–San Francisco, San Francisco, CA

**455. A Retrospective Descriptive Study of Combination Antifungal Therapies in Pediatric Oncology Patients.**

*Whitney L. Davis, Pharm.D. Candidate, William L. Greene, Pharm.D., Jerry L. Shenep, M.D., Randal T. Hayden, M.D., Brandon M. Triplett, M.D.;* St. Jude Children's Research Hospital, Memphis, TN

**456. Improved Safety of Intermittent Infusion Delivery in the Neonatal Intensive Care Unit: Establishing a Need for the Standardization of Medication Administration.**

*Amy Mitchell, Pharm.D. Candidate,<sup>1</sup> Thomas Young, M.D.,<sup>2</sup> Nancy Gary, R.N.,<sup>2</sup> Angela Peake, Pharm.D.,<sup>2</sup> Rhonda Zillmer, Pharm.D.,<sup>2</sup> Laura Hayn, Pharm.D., BCPS<sup>2</sup>;* (1) Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC; (2) WakeMed Health and Hospitals, Raleigh, NC

**Pharmacoeconomics/Outcomes**

**457. Promoting Sustainability: Advocating the Implementation of a Community-Based, Self-Managed, Pharmacist-Led Diabetes Care Program in a Coastal Community in the Philippines.**

*Marie Jett V. Cabrera, Student, Carlo Antonio G. Boado, Student, Peter F. Quilala, M.D., R.Ph.;* University of Santo Tomas, Manila, Philippines

**Pharmacoepidemiology**

**458. Drug-Induced Acute Renal Failure Using the FDA Adverse Event Reporting System Database.**

*Ali Alhammad, M.S., Abdulkhaliq J. Alsalman, M.S., Maitham A. Al Hawaj, B.S., Yousef N. Alhashem, M.S., Wally R. Smith, M.D., Spencer E. Harpe, Pharm.D., Ph.D.;* Virginia Commonwealth University, Richmond, VA

**Pharmacogenomics/Pharmacogenetics**

**459. Association Between the CYP2C9\*8 Variant and Warfarin Clearance in African Americans.**

*Katarzyna Drozda, Pharm.D. Candidate,<sup>1</sup> Harumi Takahashi, Ph.D.,<sup>2</sup> Shitalben R. Patel, M.S.,<sup>1</sup> Nancy L. Shapiro, Pharm.D., BCPS,<sup>1</sup> Edith A. Nutescu, Pharm.D.,<sup>1</sup> Larisa H. Cavallari, Pharm.D.<sup>1</sup>;* (1)University of Illinois at Chicago College of Pharmacy, Chicago, IL; (2)Meiji Pharmaceutical University, Tokyo, Japan

**461. Breast Cancer Patient Understanding and Knowledge of Pharmacogenomic Testing in Lineberger Comprehensive Cancer Center Trial 0801.**

*Andrea N. Yuen, Pharm.D. Candidate,<sup>1</sup> Jeffrey M. Peppercorn, M.D.,<sup>2</sup> Lynn G. Dressler, Ph.D.,<sup>3</sup> Wing K. Chiu, M.S.,<sup>4</sup> Christine M. Walko, Pharm.D.,<sup>1</sup> Peter Rubin, M.D.,<sup>5</sup> Oludamilola A. Olajide, M.D.,<sup>6</sup> Rachel E. Raab, M.D.,<sup>7</sup> Daniel Carrizosa, M.D.,<sup>8</sup> Steven W. Corso, M.D.,<sup>9</sup> Garry Schwartz, M.D.,<sup>10</sup> Howard L. McLeod, Pharm.D.,<sup>3</sup> Lisa A. Carey, M.D.,<sup>4</sup> William J. Irvin Jr, M.D.<sup>4</sup>;* (1)University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC; (2)Duke University, Durham, NC; (3)UNC Institute of Pharmacogenomics and Individualized Therapy, Chapel Hill, NC; (4)UNC Lineberger Comprehensive Cancer Center (LCCC), Chapel Hill, NC; (5)Moses Cone Regional Cancer Center, Greensboro, NC; (6)Rex Hematology/Oncology Associates, Raleigh, NC; (7)East Carolina University, Greenville, NC; (8)Carolinas Medical Center, Charlotte, NC; (9)

Palmetto Hematology/Oncology, Spartanburg, SC; (10)Northeast Oncology Associates, Concord, NC

**462. The Association Between NF- $\kappa$ B Gene Polymorphisms and Allograft Survival in the Hispanic Kidney Transplant Population.**

*Eunah Cho, Pharm.D. Candidate,<sup>1</sup> David Min, Pharm.D.,<sup>1</sup> Ian V. Hutchinson, Ph.D.<sup>2</sup>;* (1)Western University of Health Sciences, College of Pharmacy, Pomona, CA; (2)USC School of Pharmacy, Los Angeles, CA

**463. Effects of CYP2D6\*10/\*10 Genotype on the Pharmacokinetics of Metoclopramide.**

*Hye-In Lee, M.S.,<sup>1</sup> Chang-Ik Choi, M.S.,<sup>1</sup> Jung-Woo Bae, Ph.D.,<sup>2</sup> Choon-Gon Jang, Ph.D.,<sup>1</sup> Seok-Yong Lee, Ph.D.<sup>1</sup>;* (1)School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea; (2)College of Pharmacy, Keimyung University, Daegu, South Korea

**464. CYP2D6\*10/\*10 Genotype Significantly Affected the Pharmacokinetics of Tamsulosin.**

*Hye-In Lee, M.S.,<sup>1</sup> Chang-Ik Choi, M.S.,<sup>1</sup> Jung-Woo Bae, Ph.D.,<sup>2</sup> Choon-Gon Jang, Ph.D.,<sup>1</sup> Seok-Yong Lee, Ph.D.<sup>1</sup>;* (1)School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea; (2)College of Pharmacy, Keimyung University, Daegu, South Korea

**465. Effect of CYP2D6\*10 Allele on the Pharmacokinetics of Propranolol in Koreans.**

*Hye-In Lee, M.S.,<sup>1</sup> Chang-Ik Choi, M.S.,<sup>1</sup> Jung-Woo Bae, Ph.D.,<sup>2</sup> Choon-Gon Jang, Ph.D.,<sup>1</sup> Seok-Yong Lee, Ph.D.<sup>1</sup>;* (1)School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea; (2)College of Pharmacy, Keimyung University, Daegu, South Korea

**Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery**

**466. Characterization of Polymyxin B (PB) Against *Acinetobacter baumannii* Using Pharmacokinetic and Pharmacodynamic (PK/PD) Approaches.**

*Marie San Roman, Pharm.D. Candidate,<sup>1</sup> Brian T. Tsuji, Pharm.D.<sup>2</sup>;* (1)University at Buffalo, Buffalo, NY; (2)Laboratory for Antimicrobial Pharmacodynamics University at Buffalo, State University of New York, Buffalo, NY

**467. Attenuation of Vancomycin Pharmacodynamics (PD) Due to Dense Inoculum Methicillin-Resistant *Staphylococcus aureus* (MRSA).**

*Curtis Johnston, Pharm.D. Candidate, 2012, Brian T. Tsuji, Pharm.D.;* Laboratory for Antimicrobial Pharmacodynamics University at Buffalo, State University of New York, Buffalo, NY

**Psychiatry**

**468F. Blue Genes: Genetic Variant of Brain-Derived Neurotrophic Factor Associated with Depression Index in Post-coronary Artery Bypass Graft Patients.**

*Diana N. Pinchevsky, Pharm.D., Indrani Halder, Ph.D., Bea Herbeck Belnap, DrBiolHum, Bruce L. Rollman, M.D., MPH, Robert E. Ferrell, Ph.D., Tanya J. Fabian, Pharm.D., Ph.D., BCPP;* University of Pittsburgh, Pittsburgh, PA

**Substance Abuse/Toxicology**

**469. Benzodiazepine Use in Alcohol Withdrawal Syndrome at an Academic Medical Center.**

*Kyle A. Amelung, Pharm.D. Candidate, 2012, Eli N. Deal, Pharm.D., BCPS;* Barnes-Jewish Hospital, St. Louis, MO

## **Transplant/Immunology**

### **470F. Effectiveness and Safety of Influenza Vaccine in First 6 Months Post-lung Transplant.**

*Kalynn A. Rohde, Student, John J.M. Moran, B.S., Mary S. Hayney, Pharm.D., MPH; University of Wisconsin School of Pharmacy, Madison, WI*

## **Women's Health**

### **471. The Pharmacokinetics of Metoprolol During Pregnancy.**

*Tracy Yep, B.S.,<sup>1</sup> Sara Eyal, Ph.D.,<sup>2</sup> Thomas R. Easterling, M.D.,<sup>3</sup> Danny D. Shen, Ph.D.,<sup>4</sup> Edward J. Kelly, Ph.D.,<sup>4</sup> Gary D.V. Hankins, M.D.,<sup>5</sup> Steve Caritis, M.D.,<sup>6</sup> Linda Risler, B.S.,<sup>1</sup> Mary F. Hebert, Pharm.D., FCCP<sup>3</sup>; (1)University of Washington Department of Pharmacy, Seattle, WA; (2)Institute of Drug Research, Jerusalem, Israel; (3)University of Washington Departments of Pharmacy and Obstetrics & Gynecology, Seattle, WA; (4)University of Washington, Department of Pharmacy, Seattle, WA; (5)University of Texas Medical Branch Department of OB/GYN, Galveston, TX; (6)Magee-Women's Hospital, Pittsburgh, PA*

### **472. Computer Algorithm: A More Sensitive Tool than Standard Visual Scoring for Analyzing Immunohistochemistry Staining of the Placental Vasculature.**

*Michael P. Drozdowicz, Pharm.D. Candidate, 2012,<sup>1</sup> Katie Jaenecke, Pharm.D.,<sup>1</sup> Andrew Tong, Pharm.D.,<sup>1</sup> Albert Franco, M.D.,<sup>2</sup> Daniel Brazeau, Ph.D.,<sup>3</sup> Nilsa Ramirez, M.D.,<sup>4</sup> Thomas J. Barr, B.S., MBA,<sup>4</sup> William Beyer, BSEE, MSEE,<sup>4</sup> Patty Fan-Havard, Pharm.D.<sup>1</sup>; (1)University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Amherst, NY; (2) Carolinas Medical Center, Charlotte, NC; (3)University of New England, Portland, ME; (4) The Research Institute at Nationwide Children's Hospital, Columbus, OH*

## **LATE BREAKERS**

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoconomics, and pharmacoepidemiology.

## **ADR/Drug Interactions**

### **490. Prevalence of Adverse Drug Events in Three Veterans Affairs Nursing Homes.**

*Zachary A. Marcum, Pharm.D., M.S., Kelly L. Rovesti, Pharm.D., Michael C. Behrens, Pharm.D., Michael W. Logsdon, Pharm.D., Jill Myers, Pharm.D., Susan D. Francis, Pharm.D., Sean M. Jeffery, Pharm.D., Sherrie L. Aspinall, Pharm.D., M.S., Joseph T. Hanlon, Pharm.D., M.S., Steven M. Handler, M.D., Ph.D. University of Pittsburgh, Pittsburgh, PA; Veterans Affairs Pittsburgh Health Care System, Pittsburgh, PA; Durham Veterans Affairs Medical Center, Durham, NC; Veterans Affairs Connecticut Health Care System, West Haven, CT; Veterans Affairs Center for Medication Safety, Hines, IL*